Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04419025 |
Recruitment Status :
Completed
First Posted : June 5, 2020
Last Update Posted : May 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID Sars-CoV2 SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere Oxidative Stress | Drug: N-acetylcysteine | Phase 2 |
After being informed of the study and potential risks and benefits, patients meeting eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as follows:
Inpatients:
- N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until discharge
- N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge
Outpatients:
- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 165 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants are assigned to one of two groups in parallel for the duration of the study. One arm is the intervention arm - those receiving N-acetylcysteine (NAC). One arm is the control group - those not receiving N-acetylcysteine (NAC). |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease |
Actual Study Start Date : | September 23, 2020 |
Actual Primary Completion Date : | May 14, 2021 |
Actual Study Completion Date : | May 14, 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: NAC
Patients receiving N-acetylcysteine (NAC)
|
Drug: N-acetylcysteine
Oral formulation: 600 mg capsules of N-acetylcysteine
Other Name: NAC, acetylcysteine, N-acetyl-L-cysteine, NALC |
No Intervention: Control
Patients not receiving N-acetylcysteine (NAC)
|
- Decrease in Respiratory Rate [ Time Frame: First hour after first dose of NAC ]Decrease in dyspnea measured by respiratory rate (RR)
- Hospital length of stay (LOS) [ Time Frame: Through study completion, average 9 months ]Hospital LOS for admitted patients
- Need for mechanical ventilation [ Time Frame: Through study completion, average 9 months ]Whether a patient needed mechanical ventilation (intubation)
- Length of time intubated [ Time Frame: Through study completion, average 9 months ]If intubated, how long needing mechanical ventilation
- Need for hospitalization [ Time Frame: Through study completion, average 9 months ]Outpatients on NAC needing admission to the hospital
- Recovery disposition [ Time Frame: Through study completion, average 9 months ]Whether outpatients continued to recover as outpatients; whether admitted patients were managed on medical floors or level of care increased to ICU level of care; whether patients expired
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain
Exclusion Criteria:
- Minors, pregnant women and people unable to provide informed consent are excluded from this study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04419025
United States, Massachusetts | |
CHA Cambridge Hospital | |
Cambridge, Massachusetts, United States, 02138 | |
CHA Everett Hospital | |
Everett, Massachusetts, United States, 02149 | |
CHA Respiratory Clinic | |
Somerville, Massachusetts, United States, 02143 | |
CHA Somerville campus | |
Somerville, Massachusetts, United States, 02144 |
Responsible Party: | Melisa Lai-Becker, Chief, CHA Everett Hospital Emergency Department; Director, CHA Division of Medical Toxicology, Cambridge Health Alliance |
ClinicalTrials.gov Identifier: | NCT04419025 |
Other Study ID Numbers: |
CHA-IRB-1139/05/20 |
First Posted: | June 5, 2020 Key Record Dates |
Last Update Posted: | May 28, 2021 |
Last Verified: | May 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Information that underlies results in published data |
Supporting Materials: |
Study Protocol Informed Consent Form (ICF) |
Time Frame: | Six months after publication available for a year |
Access Criteria: | Written request; to be reviewed by the PI |
URL: | http://www.NACinCOVID.info |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Glutathione Acetylcysteine Oxidative stress NAC |
COVID COVID-19 SARS-CoV2 |
COVID-19 Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |
Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |